Beta Drugs Geçmiş Kazanç Performansı

Geçmiş kriter kontrolleri 3/6

Beta Drugs has been growing earnings at an average annual rate of 32.3%, while the Pharmaceuticals industry saw earnings growing at 13.4% annually. Revenues have been growing at an average rate of 28.4% per year. Beta Drugs's return on equity is 23.2%, and it has net margins of 12.3%.

Anahtar bilgiler

32.3%

Kazanç büyüme oranı

31.5%

EPS büyüme oranı

Pharmaceuticals Sektör Büyümesi17.5%
Gelir büyüme oranı28.4%
Özkaynak getirisi23.2%
Net Marj12.3%
Son Kazanç Güncellemesi31 Mar 2024

Yakın geçmiş performans güncellemeleri

Recent updates

Does Beta Drugs (NSE:BETA) Deserve A Spot On Your Watchlist?

Aug 30
Does Beta Drugs (NSE:BETA) Deserve A Spot On Your Watchlist?

Investors Appear Satisfied With Beta Drugs Limited's (NSE:BETA) Prospects As Shares Rocket 27%

Aug 30
Investors Appear Satisfied With Beta Drugs Limited's (NSE:BETA) Prospects As Shares Rocket 27%

Earnings Tell The Story For Beta Drugs Limited (NSE:BETA) As Its Stock Soars 29%

Dec 23
Earnings Tell The Story For Beta Drugs Limited (NSE:BETA) As Its Stock Soars 29%

Does Beta Drugs (NSE:BETA) Deserve A Spot On Your Watchlist?

Dec 11
Does Beta Drugs (NSE:BETA) Deserve A Spot On Your Watchlist?

These 4 Measures Indicate That Beta Drugs (NSE:BETA) Is Using Debt Reasonably Well

Jul 29
These 4 Measures Indicate That Beta Drugs (NSE:BETA) Is Using Debt Reasonably Well

Here's Why We Think Beta Drugs (NSE:BETA) Is Well Worth Watching

Jun 17
Here's Why We Think Beta Drugs (NSE:BETA) Is Well Worth Watching

Here's Why I Think Beta Drugs (NSE:BETA) Might Deserve Your Attention Today

Feb 21
Here's Why I Think Beta Drugs (NSE:BETA) Might Deserve Your Attention Today

Beta Drugs (NSE:BETA) Seems To Use Debt Quite Sensibly

Dec 20
Beta Drugs (NSE:BETA) Seems To Use Debt Quite Sensibly

With EPS Growth And More, Beta Drugs (NSE:BETA) Is Interesting

Nov 21
With EPS Growth And More, Beta Drugs (NSE:BETA) Is Interesting

These 4 Measures Indicate That Beta Drugs (NSE:BETA) Is Using Debt Reasonably Well

Sep 02
These 4 Measures Indicate That Beta Drugs (NSE:BETA) Is Using Debt Reasonably Well

Beta Drugs (NSE:BETA) Seems To Use Debt Quite Sensibly

May 20
Beta Drugs (NSE:BETA) Seems To Use Debt Quite Sensibly

Is Beta Drugs (NSE:BETA) A Risky Investment?

Jan 29
Is Beta Drugs (NSE:BETA) A Risky Investment?

Is Beta Drugs Limited's (NSE:BETA) Stock's Recent Performance Being Led By Its Attractive Financial Prospects?

Dec 25
Is Beta Drugs Limited's (NSE:BETA) Stock's Recent Performance Being Led By Its Attractive Financial Prospects?

Chairman & MD Vijay Batra Just Bought A Handful Of Shares In Beta Drugs Limited (NSE:BETA)

Nov 20
Chairman & MD Vijay Batra Just Bought A Handful Of Shares In Beta Drugs Limited (NSE:BETA)

Gelir ve Gider Dağılımı

Beta Drugs nasıl para kazanır ve harcar. LTM bazında en son bildirilen kazançlara dayanmaktadır.


Kazanç ve Gelir Geçmişi

NSEI:BETA Gelir, gider ve kazançlar (INR Millions )
TarihGelirKazançlarG+A GiderleriAr-Ge Giderleri
31 Mar 242,9573642770
31 Dec 232,7593562660
30 Sep 232,5603482540
30 Jun 232,4163272490
31 Mar 232,2713072430
31 Dec 222,1762982260
30 Sep 222,0812892100
30 Jun 221,9602691900
31 Mar 221,8382481700
31 Dec 211,6832161560
30 Sep 211,5281831430
30 Jun 211,3451501320
31 Mar 211,1611171210
31 Dec 201,0581061190
30 Sep 20956951030
30 Jun 2093294990
31 Mar 20908941100
30 Sep 1983297890
30 Jun 1974689760
31 Mar 1965980640
31 Mar 1850668300
31 Mar 1741743530
31 Mar 1626411320
31 Mar 153-110
31 Mar 1414020

Kaliteli Kazançlar: BETA has high quality earnings.

Büyüyen Kar Marjı: BETA's current net profit margins (12.3%) are lower than last year (13.5%).


Serbest Nakit Akışı ve Kazanç Analizi


Geçmiş Kazanç Büyüme Analizi

Kazanç Eğilimi: BETA's earnings have grown significantly by 32.3% per year over the past 5 years.

Büyüme Hızlandırma: BETA's earnings growth over the past year (18.6%) is below its 5-year average (32.3% per year).

Kazançlar vs. Sektör: BETA earnings growth over the past year (18.6%) did not outperform the Pharmaceuticals industry 19.1%.


Özkaynak Getirisi

Yüksek ROE: BETA's Return on Equity (23.2%) is considered high.


Varlık Getirisi


Kullanılan Sermaye Getirisi


Geçmişte güçlü performans gösteren şirketleri keşfedin